Notice Regarding Revision of Business Structure for Recombinant Human Serum Albumin Preparation

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President and Representative Director: Masayuki Mitsuka) decided today to revise the business structure for Medway® Injection 25%, a recombinant human serum albumin preparation.

1. Overview of Business Structure Revision

There are significant medical needs for albumin preparations with a high degree of safety, and the Medway® Injection 25% recombinant human serum albumin preparation can contribute to the policy of national self-sufficiency in plasma fractionation products. Accordingly, to contribute to national self-sufficiency and a stable supply for albumin preparations, Mitsubishi Tanabe Pharma and Bipha Corporation have worked steadily to advance preparations to resume sales of Medway® Injection 25%.

With consideration for changing the overall market for albumin preparations in recent years, Mitsubishi Tanabe Pharma thoroughly reevaluated the current business structure with the objective of supporting the stable continuation of the recombinant albumin preparation business. As a result, the Company decided to transfer the manufacturing technologies for these products, which are handled by Bipha, to an external manufacturing enterprise. In this way, plans call for Bipha to withdraw from the manufacturing of Medway.

2. Overview of Bipha Corporation

(1) Company name: Bipha Corporation
(2) Location: 1007-124, Izumisawa, Chitose City, Hokkaido
(3) Representative: President and Representative Director, Koji Yaku
(4) Lines of business: Pharmaceutical manufacturing, others
(5) Capital: ¥100 million
(6) Date of establishment: November 1, 1996
(7) Number of employees: 72 employees

3. Influence on Mitsubishi Tanabe Pharma's results

The Company will provide notice in the event that an influence on results is anticipated.

〈〈For Details, Contact the Following Section〉〉
Corporate Communications Department
Tel +81-6-6205-5211